Examines randomized controlled trial evidence on antioxidant therapies in Alzheimer's, comparing cognitive outcomes, biomarkers, and behavioral measures.
Key Takeaways
- Meta-analysis included 23 randomized controlled trials totaling 10,537 participants
- Antioxidants improved urinary 8‑iso‑prostaglandin F2α levels significantly in trials
- No significant benefits were detected on core cognitive scales ADAS-Cog or MMSE